Gritstone bio stock trades at USD 0.15 as cash remains central

Gritstone bio (ISIN US3987021022) was quoted at USD 0.15 on Nasdaq on September 22, 2026, giving the stock a concrete market reference ahead of September 23, 2026. The company reported USD 0.2 million in revenue for the second quarter of 2026, keeping clinical development and liquidity central to the investment case.

Clinical progress shapes valuation

Gritstone bio is a clinical-stage biotechnology company whose value is driven primarily by development milestones rather than established product sales. In Q2 2026, revenue of USD 0.2 million represented the commercial scale of the business, while research and development spending remained the more relevant operating indicator for the period.

The comparison with a mature biopharmaceutical company is therefore direct: Gritstone bio had quarterly revenue measured in millions of dollars, not hundreds of millions. That gap makes trial data, regulatory progress and financing capacity more important than traditional sales momentum.

Cash and financing remain key

For investors, the stock price of USD 0.15 on September 22, 2026 must be read alongside the company's cash position and quarterly operating expenses. At this share-price level, even modest changes in the number of shares outstanding can materially affect per-share value through dilution.

The most useful operating comparison is between the USD 0.2 million of Q2 2026 revenue and the cash required to fund clinical programs. Until recurring product revenue develops, the balance between available liquidity, trial spending and access to capital remains a measurable counter-factor to any positive development update.

Stock stays tied to milestones

Gritstone bio stock remains a milestone-driven security: the September 22, 2026 Nasdaq quotation supplies the market signal, while the second-quarter 2026 revenue figure shows the limited commercial base. Future valuation changes will depend on verified clinical, regulatory or financing developments rather than on current sales growth alone.

More news and analyses on Gritstone bio stock